Stock Chart

ZBIO

$18.37 -12.02%
Score: 51.9 HOLD
LEAPs: BUY $40
i
LEAPs Option Signal

Type: BUY wallstreet
Strike: $40
Premium: $1.20
Expiry: Dec 18, 2026
Target: $44
Score: 100

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $19.96 - $28.29 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.05
Vol: 0.37x (vs SPY: 0.3x | vs QQQ: 0.3x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About ZBIO - Zenas BioPharma, Inc. Common Stock

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Key Statistics

Market Cap $2B
P/E Ratio 2.61

This ZBIO stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track ZBIO's price movements with trendlines, gamma walls, and key support/resistance levels.